Literature DB >> 9171103

Analysis of the human TATA binding protein promoter and identification of an ets site critical for activity.

C E Foulds1, D K Hawley.   

Abstract

The TATA binding protein (TBP) is a general transcription factor required for initiation by all three eukaryotic nuclear RNA polymerases. Little is known about how TBP gene expression is regulated. To identify sequence elements and proteins contributing to human TBP (hTBP) gene transcription, we have characterized the promoter in two human cell lines. Multiple 5'-ends of TBP mRNA mapped throughout a 111 bp region immediately upstream of a previously reported hTBP cDNA. Upon transient transfection into cells, the hTBP 5'-flanking region was shown to contain a fairly active promoter. The cis -acting elements responsible for this promoter activity in Namalwa and HeLa cells were localized in vivo by deletion analysis. The minimal promoter defined from these experiments was a 54 bp region that encompassed all but one minor start site and contained a functional Ets protein consensus binding site, which was shown to be required for promoter activity in both cell lines. The importance of other potential elements to promoter activity was found to differ between the two cell lines. Consistent with that finding, different complexes were formed on promoter-containing DNA fragments upon incubation with nuclear extracts prepared from the different cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9171103      PMCID: PMC146735          DOI: 10.1093/nar/25.12.2485

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  9 in total

1.  The two Saccharomyces cerevisiae SUA7 (TFIIB) transcripts differ at the 3'-end and respond differently to stress.

Authors:  B C Hoopes; G D Bowers; M J DiVisconte
Journal:  Nucleic Acids Res       Date:  2000-11-15       Impact factor: 16.971

2.  Hepatitis B virus X protein induces RNA polymerase III-dependent gene transcription and increases cellular TATA-binding protein by activating the Ras signaling pathway.

Authors:  H D Wang; A Trivedi; D L Johnson
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

3.  Transcriptional regulation of the TATA-binding protein by Ras cellular signaling.

Authors:  S A Johnson; N Mandavia; H D Wang; D L Johnson
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

4.  Biochemical and genetic characterization of the dominant positive element driving transcription ofthe yeast TBP-encoding gene, SPT15.

Authors:  S C Schroeder; P A Weil
Journal:  Nucleic Acids Res       Date:  1998-09-15       Impact factor: 16.971

5.  p53 represses RNA polymerase III transcription by targeting TBP and inhibiting promoter occupancy by TFIIIB.

Authors:  Diane Crighton; Annette Woiwode; Cheng Zhang; Nihar Mandavia; Jennifer P Morton; Lorna J Warnock; Jo Milner; Robert J White; Deborah L Johnson
Journal:  EMBO J       Date:  2003-06-02       Impact factor: 11.598

6.  Epidermal growth factor receptor 1 (EGFR1) and its variant EGFRvIII regulate TATA-binding protein expression through distinct pathways.

Authors:  Jody A Fromm; Sandra A S Johnson; Deborah L Johnson
Journal:  Mol Cell Biol       Date:  2008-08-18       Impact factor: 4.272

7.  Epidermal growth factor enhances cellular TATA binding protein levels and induces RNA polymerase I- and III-dependent gene activity.

Authors:  Shuping Zhong; Cheng Zhang; Deborah L Johnson
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

8.  The possible functions of duplicated ets (GGAA) motifs located near transcription start sites of various human genes.

Authors:  Fumiaki Uchiumi; Satoru Miyazaki; Sei-ichi Tanuma
Journal:  Cell Mol Life Sci       Date:  2011-04-03       Impact factor: 9.261

9.  Elevated TATA-binding protein expression drives vascular endothelial growth factor expression in colon cancer.

Authors:  Sandra A S Johnson; Justin J Lin; Christopher J Walkey; Michael P Leathers; Cristian Coarfa; Deborah L Johnson
Journal:  Oncotarget       Date:  2017-07-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.